{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:50:48Z","timestamp":1773967848615,"version":"3.50.1"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The patient acceptable symptom state (PASS) is a reliable way to characterize a patient\u2019s satisfaction with their disease state in a \u201cYes\u201d\/\u201cNo\u201d dichotomous manner. There is limited data on the time required to reach an acceptable state in Myasthenia Gravis (MG). We aimed to determine the time to reach a first PASS \u201cYes\u201d response in patients at MG diagnosis and a PASS \u201cNo\u201d status, and also to determine the influence of various factors on this time.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We performed a retrospective study of patients diagnosed with myasthenia gravis who had an initial PASS \u201cNo\u201d response and defined the time to reach a first PASS \u201cYes\u201d by Kaplan\u2013Meier analysis. Correlations were made between demographics, clinical characteristics, treatment and disease severity, using the Myasthenia Gravis Impairment Index (MGII) and Simple Single Question (SSQ).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In 86 patients meeting inclusion criteria, the median time to PASS \u201cYes\u201d was 15\u2009 months (95% CI 11\u201318). Of 67 MG patients who achieved PASS \u201cYes,\u201d 61 (91%), achieved it by 25\u2009 months after diagnosis. Patients who required only prednisone therapy achieved PASS \u201cYes\u201d in a shorter time with a median of 5.5\u2009 months (<jats:italic>p<\/jats:italic>\u2009=\u20090.01). Very-late-onset MG patients reached PASS \u201cYes\u201d status in a shorter time (HR\u2009=\u20091.99, 95% CI 0.26\u20132.63; <jats:italic>p<\/jats:italic>\u2009=\u20090.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Most patients reached PASS \u201cYes\u201d by 25 \u2009months after diagnosis. MG patients who only required prednisone and those with very-late-onset MG reach PASS \u201cYes\u201d in shorter intervals.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2023.1187189","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T06:12:46Z","timestamp":1686895966000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Time to achieve a patient acceptable symptom state in myasthenia gravis"],"prefix":"10.3389","volume":"14","author":[{"given":"Rodrigo","family":"Martinez-Harms","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera","family":"Bril","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1080\/14737175.2018.1491310","article-title":"Advances in autoimmune myasthenia gravis management [internet]","volume":"18","author":"Wang","year":"2018","journal-title":"Expert Rev Neurother"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ncl.2018.01.002","article-title":"Generalized myasthenia gravis: classification, clinical presentation, natural history, and epidemiology","volume":"36","author":"Hehir","year":"2018","journal-title":"Neurol Clin"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mus.20950","article-title":"Lifetime course of myasthenia gravis","volume":"37","author":"Grob","year":"2008","journal-title":"Muscle Nerve"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1111\/j.1749-6632.1987.tb51317.x","article-title":"The course of myasthenia gravis and therapies affecting outcome","volume":"505","author":"Grob","year":"1987","journal-title":"Ann N Y Acad Sci"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jns.2008.05.023","article-title":"Prognosis of ocular myasthenia in Korea: a retrospective multicenter analysis of 202 patients","volume":"273","author":"Hong","year":"2008","journal-title":"J Neurol Sci"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12883-017-0857-7","article-title":"Clinical predictors for the prognosis of myasthenia gravis","volume":"17","author":"Wang","year":"2017","journal-title":"BMC Neurol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1002\/mus.27369","article-title":"Clinical profile and impact of comorbidities in patients with very-late-onset myasthenia gravis","volume":"64","author":"Vijayan","year":"2021","journal-title":"Muscle Nerve"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1016\/S0003-4975(02)04083-3","article-title":"Prognostic significance of thymomas in patients with myasthenia gravis","volume":"74","author":"de Perrot","year":"2002","journal-title":"Ann Thorac Surg"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1002\/mus.27220","article-title":"Thymoma pathology and myasthenia gravis outcomes [internet]","volume":"63","author":"Menon","year":"2021","journal-title":"Muscle Nerve"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1212\/WNL.0000000000002971","article-title":"Development and validation of the myasthenia gravis impairment index","volume":"87","author":"Barnett","year":"2016","journal-title":"Neurology"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1212\/WNL.0000000000004676","article-title":"Myasthenia gravis impairment index","volume":"89","author":"Barnett","year":"2017","journal-title":"Neurology"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/mus.25720","article-title":"The utility of a single simple question in the evaluation of patients with myasthenia gravis","volume":"57","author":"Abraham","year":"2018","journal-title":"Muscle Nerve"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e1617","DOI":"10.1212\/WNL.0000000000010574","article-title":"Patient-acceptable symptom states in myasthenia gravis","volume":"95","author":"Mendoza","year":"2020","journal-title":"Neurology"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1111\/ene.14397","article-title":"Comparison of the single simple question and the patient acceptable symptom state in myasthenia gravis","volume":"27","author":"Menon","year":"2020","journal-title":"Eur J Neurol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/wnl.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis [internet]","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/mus.23330","article-title":"Recommendations for myasthenia gravis clinical trials [internet]","volume":"45","author":"Benatar","year":"2012","journal-title":"Muscle Nerve"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e1171","DOI":"10.1212\/WNL.0000000000008903","article-title":"Clinical and therapeutic features of myasthenia gravis in adults based on age at onset","volume":"94","author":"Cort\u00e9s-Vicente","year":"2020","journal-title":"Neurology"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1212\/WNL.51.4.1198","article-title":"The long-term clinical outcome of myasthenia gravis in patients with thymoma","volume":"51","author":"Bril","year":"1998","journal-title":"Neurology"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1080\/14656566.2019.1682548","article-title":"Current pharmacotherapeutic options for myasthenia gravis","volume":"20","author":"Barnett","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/mus.26695","article-title":"Cross-sectional analysis of the myasthenia gravis patient registry: disability and treatment","volume":"60","author":"Cutter","year":"2019","journal-title":"Muscle Nerve"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1177\/1359105313504235","article-title":"Trajectories of illness perceptions in persons with chronic illness: an explorative longitudinal study","volume":"20","author":"Bonsaksen","year":"2015","journal-title":"J Health Psychol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1002\/art.24674","article-title":"Illness perceptions in patients with osteoarthritis: change over time and association with disability","volume":"61","author":"Bijsterbosch","year":"2009","journal-title":"Arthritis Rheum"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1187189\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T06:12:49Z","timestamp":1686895969000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1187189\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,16]]},"references-count":23,"alternative-id":["10.3389\/fneur.2023.1187189"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2023.1187189","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,16]]},"article-number":"1187189"}}